{"id":"monoclonal-antibody-bec2","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"BEC2 recognizes and binds to GD3, a glycolipid antigen expressed on melanoma and other cancer cells. By coating tumor cells with antibody, BEC2 facilitates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), recruiting the patient's immune system to eliminate malignant cells. It has been investigated as both a therapeutic agent and as part of cancer vaccine strategies.","oneSentence":"BEC2 is a monoclonal antibody that targets GD3 ganglioside on tumor cell surfaces to trigger immune-mediated destruction of cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:02.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (advanced or metastatic)"},{"name":"Small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT00006352","phase":"PHASE3","title":"Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1999-09","conditions":"Lung Cancer","enrollment":453},{"nctId":"NCT00003279","phase":"PHASE3","title":"Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-03","conditions":"Lung Cancer","enrollment":500},{"nctId":"NCT00037713","phase":"PHASE3","title":"Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"1998-09","conditions":"Carcinoma, Small Cell Lung","enrollment":515}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"monoclonal antibody BEC2","genericName":"monoclonal antibody BEC2","companyName":"European Organisation for Research and Treatment of Cancer - EORTC","companyId":"european-organisation-for-research-and-treatment-of-cancer-eortc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Monoclonal antibody BEC2 is a treatment being studied for small cell lung carcinoma and lung cancer. It targets disialoganglioside GD2, a molecular target identified by ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}